Editing cells in place: Targeted in vivo gene editing of hematopoietic stem cells.

Antibody-engineered lipid nanoparticles enable efficient, durable in vivo editing of human hematopoietic stem cells, advancing gene therapy for blood disorders.

• Why it matters: Current ex vivo HSC gene therapy faces significant manufacturing hurdles, limiting widespread clinical application. Developing in vivo methods could overcome these barriers and improve treatment accessibility.
• What they did: The study used antibody-engineered lipid nanoparticles to target and edit HSCs directly within living organisms, demonstrating high efficiency and long-lasting effects in humanized mice models.
• The result: This approach offers a promising therapeutic strategy for genetic blood diseases, potentially simplifying treatment processes and expanding the reach of gene therapy.